Novartis AG: Number of Employees 2010-2022 | NVS

Interactive chart of Novartis AG (NVS) annual worldwide employee count from 2010 to 2022.
  • Novartis AG total number of employees in 2021 was 104,323, a 1.39% decline from 2020.
  • Novartis AG total number of employees in 2020 was 105,794, a 1.81% increase from 2019.
  • Novartis AG total number of employees in 2019 was 103,914, a 16.98% decline from 2018.
  • Novartis AG total number of employees in 2018 was 125,161, a 2.93% increase from 2017.
Novartis AG Annual Number of Employees
2021 104,323
2020 105,794
2019 103,914
2018 125,161
2017 121,597
2016 123,000
2015 118,700
2014 133,413
2013 135,696
2012 127,724
2011 123,686
2010 119,418
2009 99,834
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $204.125B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $472.231B 18.16
Pfizer (PFE) United States $302.932B 10.57
Eli Lilly (LLY) United States $297.837B 35.14
AbbVie (ABBV) United States $266.074B 11.66
Merck (MRK) United States $233.434B 13.19
GlaxoSmithKline (GSK) United Kingdom $112.907B 13.18
Novo Nordisk (NVO) Denmark $0.000B 31.73